BCLI vs. CSBR, LIFE, VIGL, SGMO, OMGA, DBVT, ATHA, BLUE, JATT, and DTIL
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Champions Oncology (CSBR), aTyr Pharma (LIFE), Vigil Neuroscience (VIGL), Sangamo Therapeutics (SGMO), Omega Therapeutics (OMGA), DBV Technologies (DBVT), Athira Pharma (ATHA), bluebird bio (BLUE), JATT Acquisition (JATT), and Precision BioSciences (DTIL). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology (NASDAQ:CSBR) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
In the previous week, Champions Oncology had 26 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 28 mentions for Champions Oncology and 2 mentions for Brainstorm Cell Therapeutics. Champions Oncology's average media sentiment score of 1.22 beat Brainstorm Cell Therapeutics' score of 1.04 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.
Champions Oncology has higher revenue and earnings than Brainstorm Cell Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 45.7% of Champions Oncology shares are held by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Brainstorm Cell Therapeutics' net margin of -19.76%. Champions Oncology's return on equity of 0.00% beat Brainstorm Cell Therapeutics' return on equity.
Champions Oncology has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Champions Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 65.56%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Champions Oncology is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics received 141 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 63.60% of users gave Brainstorm Cell Therapeutics an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Summary
Champions Oncology beats Brainstorm Cell Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
